Stock KZR KEZAR LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.705 USD -3.24% Intraday chart for Kezar Life Sciences, Inc. -7.93% -25.59%
May. 09 Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Kezar Life Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

89c4d.ZCIW4u_M6y9EmnZ2bqZwq-D2L9_rRjP3_lucLc0P8uw.V0Qvl6aOrX4r9QA9Ks9B5pDPHIzZMmWPuWPUea83h9gPTSTTh5SkYhuqOw~108ce02115d77410aca6a35446db57ed

Analyst Recommendations on Kezar Life Sciences, Inc.

Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating MT
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy MT
HC Wainwright Raises Kezar Life Sciences Price Target to $20 From $18, Maintains Buy Rating MT
Wells Fargo Downgrades Kezar Life Sciences to Equalweight From Overweight MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $18 From $19, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $19 From $21, Keeps Buy Rating MT
Wells Fargo Trims Kezar Life Sciences Price Target to $13 From $14, Maintains Overweight Rating MT
William Blair Downgrades Kezar Life Sciences to Market Perform From Outperform MT
Wells Fargo Cuts Price Target on Kezar Life Sciences to $14 From $17, Maintains Overweight Rating MT
Wells Fargo Adjusts Kezar Life Sciences Price Target to $17 From $13, Maintains Overweight Rating MT
Wells Fargo Adjusts Kezar Life Sciences' Price Target to $14 from $19, Keeps Overweight Rating MT
Wall Street Set for Higher Open Ahead of Fed Funds Rate Announcement, ISM's Services Index MT
HC Wainwright Adjusts Kezar Life Sciences' Price Target to $22 From $20, Keeps Buy Rating MT
Wells Fargo Starts Kezar Life Sciences at Overweight With $19 Price Target MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $20 from $12, Keeps Buy Rating MT
KEZAR LIFE SCIENCES : JonesTrading Starts Kezar Life Sciences at Buy With $14 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.705 USD
Average target price
11.67 USD
Spread / Average Target
+1,554.85%
High Price Target
20 USD
Spread / Highest target
+2,736.88%
Low Price Target
2 USD
Spread / Lowest Target
+183.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kezar Life Sciences, Inc.

Wells Fargo Securities
JonesTrading Institutional Services
HC Wainwright
William Blair & Co.

Ratings for Kezar Life Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KZR Stock
  4. Consensus Kezar Life Sciences, Inc.